CVS Health Corporation $CVS Stock Holdings Reduced by Holocene Advisors LP

Holocene Advisors LP cut its position in shares of CVS Health Corporation (NYSE:CVS) by 29.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,668,227 shares of the pharmacy operator’s stock after selling 705,715 shares during the period. Holocene Advisors LP owned 0.13% of CVS Health worth $125,768,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in CVS. Harbor Capital Advisors Inc. increased its holdings in CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 142 shares during the last quarter. Corundum Trust Company INC acquired a new stake in CVS Health in the third quarter valued at approximately $29,000. Front Row Advisors LLC lifted its stake in CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 371 shares during the last quarter. Twin Peaks Wealth Advisors LLC bought a new stake in CVS Health in the second quarter worth approximately $36,000. Finally, SOA Wealth Advisors LLC. increased its stake in shares of CVS Health by 36.9% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Mizuho lifted their price objective on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Wolfe Research cut their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Truist Financial set a $100.00 price target on CVS Health in a research report on Wednesday, December 10th. Argus decreased their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

CVS Health Price Performance

Shares of CVS Health stock opened at $76.14 on Monday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The company has a market cap of $96.87 billion, a PE ratio of 55.17, a price-to-earnings-growth ratio of 0.79 and a beta of 0.49. The firm has a fifty day moving average price of $78.17 and a two-hundred day moving average price of $77.83. CVS Health Corporation has a fifty-two week low of $58.35 and a fifty-two week high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The business’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.5%. CVS Health’s dividend payout ratio is 192.75%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.